Rutul Shah Sells 33,772 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 33,772 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $6.50, for a total transaction of $219,518.00. Following the transaction, the chief operating officer owned 497,751 shares of the company’s stock, valued at $3,235,381.50. This represents a 6.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Trading Down 1.2%

Shares of Precigen stock opened at $6.53 on Wednesday. Precigen, Inc. has a twelve month low of $1.70 and a twelve month high of $6.80. The firm’s 50-day moving average price is $5.07 and its 200 day moving average price is $4.44. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The firm has a market capitalization of $2.33 billion, a PE ratio of -5.53 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. The company’s revenue was up 6322.7% compared to the same quarter last year. On average, sell-side analysts predict that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Q2 results exceeded expectations. Precigen reported diluted EPS of $0.05, compared with analyst estimates for a loss of roughly $0.01–$0.02 and a loss of $0.11 a year earlier. Revenue reached $54.98 million, nearly double consensus expectations of approximately $28 million and up 6,322.7% year over year. Precigen Q2 earnings and revenues surpass estimates
• Positive Sentiment: PAPZIMEOS is driving commercial momentum. The therapy generated $53.1 million in second-quarter net revenue—more than twice the prior quarter—while patient-hub enrollment exceeded 500. Precigen said the revenue ramp helped produce quarterly profitability and could support cash-flow break-even by the end of 2026. The FDA also granted PAPZIMEOS seven-year market exclusivity. Precigen second-quarter financial results
• Positive Sentiment: Analyst support and options activity remain bullish. HC Wainwright reaffirmed a Buy rating with a $14 price target, while the reported analyst median target is $12.50. Call-option volume also surged well above typical levels, suggesting increased speculative bullish interest.
• Neutral Sentiment: Institutional positioning is mixed. Ninety-one institutions added PGEN shares in the latest quarter, while 65 reduced positions. Reported analyst ratings span Buy, Hold, and Sell, resulting in an overall consensus rating of Hold despite targets above the current trading range.
• Negative Sentiment: Insider selling could weigh on sentiment. Executives have reported open-market sales but no purchases during the past six months. COO Rutul Shah sold 33,772 shares for approximately $219,500 under a pre-arranged Rule 10b5-1 plan; other senior insiders have also sold shares.
• Negative Sentiment: Cash-flow risk remains. Precigen used $17.8 million in operating cash during the quarter, and reported liabilities of $126.7 million. Although cash, equivalents, and investments totaled $38.7 million at June 30, continued spending and the company’s highly unprofitable historical net margin remain risks if PAPZIMEOS growth slows.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PGEN shares. Citizens Jmp lifted their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Wall Street Zen cut Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Precigen in a research report on Monday. Finally, Citigroup reiterated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Precigen has an average rating of “Hold” and a consensus target price of $12.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Occam Crest Management LP lifted its position in shares of Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after purchasing an additional 799,339 shares during the last quarter. KBC Group NV purchased a new stake in Precigen during the 1st quarter worth about $1,338,000. UBS Group AG boosted its position in shares of Precigen by 41.4% during the 4th quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock worth $3,726,000 after acquiring an additional 260,824 shares in the last quarter. Investment Insight Wealth Management LLC acquired a new stake in shares of Precigen during the 4th quarter worth about $443,000. Finally, Impala Asset Management LLC purchased a new stake in Precigen during the fourth quarter worth approximately $690,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.